Surrozen Stock Quote SRZN - Stock Price, News, Charts, Message Board, Trades

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

8.29

Bid

8.00

Ask

8.54

Volume

10,405

8.04 Day's Range 9.105

4.50 52 Week Range 16.19

Market Cap

28.789M

Previous Close

9.00

Open

9.00

Last Trade

100

8.29

Last Trade Time

Financial Volume

$ 91,745

VWAP

8.8174

Average Volume (3m)

9,337

Shares Outstanding

3,198,786

Dividend Yield

PE Ratio

-0.62

Earnings Per Share (EPS)

-13.46

Revenue

Net Profit

-43.04M

Surrozen Inc is a class of therapeutics to treat serious diseases characterized by tissue injury. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), and SZN-043 (E3/ASGR1, SWEETS). Surrozen Inc is a class of therapeutics to treat serious diseases characterized by tissue injury. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), and SZN-043 (E3/ASGR1, SWEETS).

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.surrozen.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Surrozen Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker SRZN. The last closing price for Surrozen was $9. Over the last year, Surrozen shares have traded in a share price range of $ 4.50 to $ 16.19.

Surrozen currently has 3,198,786 shares outstanding. The market capitalization of Surrozen is $28.79 million. Surrozen has a price to earnings ratio (PE ratio) of -0.62.

Surrozen Publishes Study in ‘eLife’ Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling

Targeted protein degradation (TPD*) technologies have demonstrated the potential to produce novel treatment approaches Surrozen’s current SWEETS bispecific antibodies are unique TPD technologies...

Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan

SZN-043 is a novel biotherapeutic shown to potentiate Wnt signaling and induce proliferation of hepatocytes in preclinical models Treatment with SZN-043 in the Phase 1a trial was safe and well...

Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis

SZN-043 is a novel hepatocyte-specific R-spondin mimetic bispecific fusion protein targeting ASGR1Anticipate potential proof-of-concept data available in the first half of 2025 SOUTH SAN...

Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting

In preclinical models of cornea endothelial dystrophies, a Surrozen antibody-based Wnt mimetic reduced corneal edema and stimulated endothelial cell proliferation in the corneaSurrozen’s antibody...

Surrozen Provides First Quarter 2024 Financial Results and Business Update

SZN-043 Phase 1a clinical trial results to be presented at the 2024 European Association for the Study of the Liver (EASL) in Milan Preclinical data from ARVO 2024 demonstrate the promise of a...

Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis

In a preclinical model of pulmonary fibrosis, a Surrozen antibody-based SWAP platform molecule decreased pulmonary inflammation and fibrosis and improved lung function Surrozen Wnt mimetic SWAP...

Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043

-Phase 1a trial demonstrated acceptable safety and tolerability with no reported serious adverse events-Phase 1a data demonstrated target engagement, a pharmacodynamic effect and effects on liver...

Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules

- $17.5 million upfront proceeds with up to an additional $175 million of proceeds upon the exercise of warrants- Initial capital funds expansion of Phase 1b trial in severe alcohol-associated...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-1.06	-11.3368983957	9.35	9.9899	8.04	4178	9.29560947	CS
4	-1.45	-14.887063655	9.74	11	8.04	7034	9.74509605	CS
12	-0.69	-7.68374164811	8.98	11.99	8.04	9337	10.23965459	CS
26	-0.01	-0.120481927711	8.3	16.19	7.15	13080	10.7349489	CS
52	-4.6565	-35.9672498359	12.9465	16.19	4.5	57178	8.35560913	CS
156	-134.96	-94.2129144852	143.25	210	4.5	168199	31.09767687	CS
260	-134.96	-94.2129144852	143.25	210	4.5	168199	31.09767687	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
MIRAMIRA Pharmaceuticals Inc	$ 5.01 (627.35%)	158.14M
CMAXCareMax Inc	$ 5.19 (228.48%)	102.64M
NUKKNukkleus Inc	$ 0.499 (55.94%)	26.2M
SNOASonoma Pharmaceuticals Inc	$ 0.423 (37.34%)	4.88M
ONDSOndas Holdings Inc	$ 1.1297 (34.06%)	2.19M
LGCBLinkage Global Inc	$ 3.6601 (-29.82%)	168k
CGBSCrown LNG Holdings Ltd	$ 0.9997 (-29.10%)	3.39M
SPECSpectaire Holdings Inc	$ 0.3962 (-24.53%)	1.87M
GSUNGolden Sun Health Technology Group Ltd	$ 5.13 (-23.66%)	158.79k
PSNLPersonalis Inc	$ 2.9808 (-22.58%)	3.11M
NVDANVIDIA Corporation	$ 123.54 (4.76%)	239M
SQQQProShares UltraPro Short QQQ	$ 8.09 (-4.37%)	183.65M
MIRAMIRA Pharmaceuticals Inc	$ 5.01 (627.35%)	158.14M
SERVServe Robotics Inc	$ 8.73 (15.63%)	151.56M
NCPLNetcapital Inc	$ 0.1118 (7.50%)	124.37M